Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani

By Paraguai de Souza E.   Bernardo R.R.   Palatnik M.   Palatnik de Sousa C.B.  

Vaccine, Vol. 19, Iss. 23, 2001-04 ,pp. : 3104-3115

Elsevier

Access to resources Recommend Favorite

A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis

By Gonzalo R.M.   del Real G.   Rodriguez J.R.   Rodriguez D.   Heljasvaara R.   Lucas P.   Larraga V.   Esteban M.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1226-1231

Elsevier

Access to resources Recommend Favorite

Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8 + T lymphocyte activation

By Rafati S.   Kariminia A.   Seyde-Eslami S.   Narimani M.   Taheri T.   Lebbatard M.  

Vaccine, Vol. 20, Iss. 19, 2002-06 ,pp. : 2439-2447

Elsevier

Access to resources Recommend Favorite

Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background

By Chen W.   Shen H.   Webb A.   KuoLee R.   Conlan J.W.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3690-3700

Elsevier

Access to resources Recommend Favorite

Intranasal IFN- gene transfer protects BALB/c mice against respiratory syncytial virus infection

By Kumar M.   Behera A.K.   Matsuse H.   Lockey R.F.   Mohapatra S.S.  

Vaccine, Vol. 18, Iss. 5, 1999-10 ,pp. : 558-567

Elsevier

Access to resources Recommend Favorite